ReviewThe Korean journal of pain2020
Recombinant zoster vaccine (Shingrix
Review in The Korean journal of pain, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- A European Delphi Consensus to Support the Diagnosis, Management, and Appropriate Positioning of Topical Treatments for Postherpetic Neuralgia (PHN).Pain and therapy · 2026Article
- Characterization of lipid solubilization, bicelle formation, and magnetic-alignment induced by saponins.Journal of colloid and interface science · 2026Article
- A multicenter prospective cohort study developing and validating a SIRI-based machine learning model and simplified risk score for predicting postherpetic neuralgia.Frontiers in immunology · 2026Article
- The characterization of a rhamnosylated triterpenic saponin fromFrontiers in pharmacology · 2026Article
- Vaccines for microbial eye diseases in the era of data science: opportunities and challenges.Frontiers in immunology · 2026Review
- Designing of multi-epitope vaccine against Varicella zoster virus (VZV) using immunoinformatics and structural analysis: In silico study.BioImpacts : BI · 2025Article
- Expanded spectrum of varicella disease and the need for vaccination in India.Human vaccines & immunotherapeutics · 2024Article
- Nanomaterials in Drug Delivery: Strengths and Opportunities in Medicine.Molecules (Basel, Switzerland) · 2024Review
- Designing a polyvalent vaccine targeting multiple strains of varicella zoster virus using integrated bioinformatics approaches.Frontiers in microbiology · 2023Article
- The Impact of Routine Vaccinations on Alzheimer's Disease Risk in Persons 65 Years and Older: A Claims-Based Cohort Study using Propensity Score Matching.Journal of Alzheimer's disease : JAD · 2023Article
- Current scenario and future applicability of antivirals against herpes zoster.The Korean journal of pain · 2023Review
- Adult preventive vaccines with other synergistic lifestyle options: is it time to add these ancillary benefits to the overall AS management checklist?World journal of urology · 2022Review
- Novel approaches for vaccine development.Cell · 2021Review
- Vaccine approaches for antigen capture by liposomes.Expert review of vaccinesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postherpetic neuralgia (PHN) is a challenging condition for pain management specialists. The prevention of herpes zoster (HZ) and subsequent PHN in individuals aged 50 years and older, via the development of new vaccines, is an ongoing research project. The live zoster vaccine (LZV, Zostavax
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.